Recent Advances in Colorectal Cancer Research

Colorectal cancer is the second leading cause of cancer death in the United States. More than 50,000 people are estimated to have died from colorectal cancer in the United States last year, according to federal statistics.

Colorectal cancer typically begins as a slow-growing, noncancerous polyp which, over time, can progress to invasive cancer. If a cancerous polyp isn’t removed, it can penetrate the lining of the large intestine, allowing the cancer to spread to other organs through blood or lymph vessels. With screening, it is possible to detect and remove polyps before they become cancerous. An increase in colorectal cancer awareness and screening has most likely contributed to the overall reduction in colorectal cancer incidence in the last 30 years.

As March is Colorectal Cancer Awareness Month, we’ve put together a selection of recent colorectal cancer studies across the AACR portfolio along with screening recommendations and risk factors associated with this disease.

Read More

Hyperglycemia and Aggressive Prostate Cancer Risk

Rates of diabetes in the United States are increasing. According to statistics from the Centers for Disease Control and Prevention (CDC), an estimated 23 million Americans received a diagnosis of diabetes in 2015, in contrast to 1.6 million Americans in 1958. Our risk for diabetes increases as we age; over 25 percent of those ages 65 or older had diabetes in 2015, according to the CDC.

Diabetes is a risk factor for several types of cancer, including liver, pancreatic, and endometrial cancers. While this association is complex, some possible biological links include insulin resistance and hyperglycemia.

Previous work to understand the relationship between hyperglycemia and prostate cancer risk and mortality have yielded mixed results. A recent study published in Cancer Prevention Research evaluated whether hyperglycemia, as measured through multiple biomarkers, is associated with prostate cancer incidence and mortality.

Read More

AACR Journals Editors’ Picks for February

As a regular post on this blog, we feature the 10 articles chosen by our editors from all journal issues published each month by the American Association of Cancer Research (AACR). For February, these articles span from a review of recent preclinical studies focused on brain metastases to a first-in-human immunotherapy trial. As always, articles highlighted here are freely available for a limited time.

Read More

From the Journals: Editors’ Picks for January

Back for the new year, here are the editors’ selections for the January issues of the eight scientific journals published by the American Association for Cancer Research (AACR). Featured research highlights a wide variety of cancer-related topics, spanning from preclinical therapeutic strategies to cancer prevention. All articles summarized here are freely available for a limited time.

Read More

December Editors’ Picks from AACR Journals

The staff of Cancer Research Catalyst was pleased to introduce a new feature this year: Editors’ Picks, a monthly collection of articles selected by the editors of the eight scientific journals published by the American Association for Cancer Research (AACR). To wrap up the year, here are the editors’ choices for December. As always, these articles are freely available for a limited time.

Read More

AACR Journals Editors’ Picks for November

Every month, the editors from the eight scientific journals published by the American Association for Cancer Research (AACR) select one “must read” article from each issue. Highlighted research encompasses a wide variety of cancer-related discoveries, including basic scientific investigation and epidemiological studies. Read on to learn about this month’s selections, which are freely accessible for a limited time.

Read More

Can Artificial Intelligence Help Reduce False-positive Mammograms?

In a study published in the AACR’s journal Clinical Cancer Research, a team of scientists from the University of Pittsburgh discuss yet another area of cancer research where artificial intelligence (AI) can potentially solve a decades-long problem: false-positive results and high patient recall rates from breast cancer screening mammography.

Read More

Harnessing the Power of Precision Medicine – Treating Cancers with Tissue-agnostic Therapies

Cancer treatments have been, and continue to be in most cases, based on the organ site where the tumor originates—some treatments are specific for breast cancer, some for lung cancer, and so on. However, rapid advances in genomic sequencing technologies have led to a recent development that deviates from the long-held notion of treating cancers based on the site of origin.

Read More